Pancreatic Stenting Reduces Post-ERCP Pancreatitis and Biliary Sepsis in High-Risk Patients: A Randomized, Controlled Study

Table 1

Baseline demographic and clinical characteristics of patients.

	Experimental group ()	Control group ()
Age, year, mean ± SD	57.2 ± 14.4	57.4 ± 13.9	0.924
Sex, male/female	59/45	55/47	0.685
ERCP indications, (%)
CBD gallstone	72 (69.2)	60 (58.8)	0.120
Bile duct dilation	3 (2.9)	5 (4.9)	0.454
Cholangitis	2 (1.9)	1 (1.0)	0.572
Malignant CBD stricture	24 (23.1)	34 (33.3)	0.102
Pancreatic cancer	9 (8.7)	4 (3.9)	0.163
Duodenal papillitis	2 (1.9)	1 (1.0)	0.572
Sclerosing cholangitis	1 (1.0)	1 (1.0)	0.989
Concomitant liver fluke disease, (%)	31 (29.8)	32 (31.4)	0.807
Complicating risk factors, (%)
Complicating 2 risk factors	22 (21.2)	29 (28.4)	0.226
Complicating 3 risk factors	25 (24.0)	32 (31.4)	0.239
Complicating 4 risk factors	38 (36.5)	25 (24.5)	0.061
Complicating ≥ 5 risk factors	19 (18.3)	16 (15.7)	0.622